ClinicalTrials.gg
Drug

Penpulimab clinical trials

Also written AK105.

studies test it
65
open now
23
in phase 3
7
first study started
2018

How each study uses penpulimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the penpulimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Apr 2025 · PENPULIMAB-KCQX · BLA 761258 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Penpulimab
16
Penpulimab injection
6
AK105 injection
3

Development codes

AK105
18

In one entry with another drug

Given together, or one or the other

Anlotinib Plus Penpulimab
2
Anlotinib & Penpulimab
2

Studies by the year they started

65 studies that test it; most in 2022 (23)

Studies that test penpulimab, by start year
YearStudies
20185
20192
20205
20218
202223
202312
20247
20251
20262

Who runs them

Industry 27 · Other 38

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (16) · Akeso (8) · Peking Union Medical College Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (4) · The First Affiliated Hospital of Zhengzhou University (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · Hunan Cancer Hospital (2) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (2)

Often tested with

Tested in the same studies.

Anlotinib (25) · Catequentinib hydrochloride (11) · Anti-TIM-3 Monoclonal Antibody TQB2618 (4) · Disitamab vedotin (3) · Oxaliplatin (3) · Anti-LAG-3 Monoclonal Antibody TQB2223 (2) · Proteasome Inhibitor TQB3602 (1) · TQB2916 (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test penpulimab, phase 3 first.

Studies

Open first, then newest update. How each study uses penpulimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 65

See all 65 studies that test penpulimab →

Given beside what is tested · 7 — penpulimab is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with penpulimab

Codes

What other systems call penpulimab · ClinicalTrials.gg INT001779

  • MeSH (NLM) C000720860penpulimabOne source NLM
  • UNII (FDA) IBS1BZ4E4IPENPULIMABConfirmed FDA, NLM
  • NCI Thesaurus C155879PenpulimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.